The first inhaled antibiotic in China is here

Medical Network, September 3 News On September 1, Joincare was accepted by the CDE for the application of tobramycin inhalation solution for the new drug category 2.
4.
At present, no inhaled antibacterial drugs have been approved in China
.
According to data from Mi Nei.
com, the market size of the terminal systemic antibacterial drugs for China's public medical institutions and Chinese urban physical pharmacies exceeds 120 billion yuan in 2020, and the growth rate has declined for the first time in nearly 5 years
.
Source: CDE official website Tobramycin is an aminoglycoside antibiotic.
It binds to the 30S subunit of the bacterial ribosome to inhibit the synthesis of bacterial protein and exerts an antibacterial effect.
It is used for infections caused by Staphylococcus and Gram-negative bacilli
.
At present, the main dosage forms of tobramycin that have been marketed in China are injections and eye drops.
According to data from Minnet, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and The total market size of tobramycin for physical pharmacies in cities in China exceeded 200 million yuan, a year-on-year decline
.
Source of clinical development of tobramycin inhalation solution: Mynet.
com China Drug Clinical Trial Publicity LibraryHealth Yuan's tobramycin inhalation solution is an antibacterial drug developed for the high incidence of bronchiectasis and the lack of clinical drugs in China The new inhalation preparation is the first inhaled antibiotic drug that has submitted a marketing application in China
.
In recent years, the domestic systemic antibacterial drug market has been under pressure due to the impact of policies such as restricted transportation and resistance, and the growth rate has slowed year by year.
In 2020, the impact of the epidemic will be superimposed, and the growth rate will decline for the first time
.
Among them, the market size of physical pharmacies in Chinese cities exceeds 7 billion yuan, and the decline is much smaller than that of public medical institutions in China
.
Sales of terminal systemic antibacterial drugs in physical pharmacies in cities in China (unit: 10,000 yuan) Source: Mi Nei.
com Competitive pattern of physical pharmacies in cities in China as the leader on the inhalation trackIn the enterprise , at present, Health Yuan has 4 inhalants approved for marketing and deemed to have been reviewed, of which levalbuterol hydrochloride inhalation solution, ipratropium bromide solution for inhalation, and compound ipratropium bromide inhalation solution were the first to have been reviewed
.
The source of inhalants approved for marketing of Joincare: Meinenet MED2.
0 Chinese Drug Evaluation Database In addition, ipratropium bromide aerosol, indacaterol maleate powder inhalation, terbutaline sulfate nebulization Inhalation solutions, mometasone furoate nasal spray, budesonide inhalation aerosol and other inhalants have also submitted marketing applications and are currently under review
.
  　　Source: Mi Nei.
com database, CDE official website.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of urban entity that covers 293 prefectures and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors the entire category Pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of September 2nd, if there are any omissions, please correct me!